Non-comparative phase II RCT in 141 cisplatin-ineligible patients with R/M HNSCC: 2-year OS was 24.7% with nivolumab plus paclitaxel vs 13.4% with cetuximab, meeting the endpoint, but mortality was higher with nivotax (18% vs 8.3%), mainly respiratory events.
RCTn = 141
Docampo et al. Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study